United States Patent 11,433,078 (Meloxicam + Rizatriptan) for Migraine: Claim Scope and US Patent Landscape
US Drug Patent 11,433,078 claims a specific oral combination and a specific pharmacokinetic (PK) exposure window for meloxicam paired with a clinical outcome advantage over rizatriptan alone. The claims are dominated by (i) dosing ranges for rizatriptan (free base equivalents) and meloxicam, (ii) a single dosage form with defined meloxicam mean Tmax ≤110 minutes and AUC0-24 ~30–50 μg·hr/mL, and (iii) superiority at timepoints (30 min, 1.5 h, 2 h, 24 h) against the same rizatriptan amount administered alone. Dependent claims narrow to a meloxicam sulfobutylether-β-cyclodextrin complex, bicarbonate (including sodium bicarbonate), and monolayer tablet composition.
Core value of the estate for a generic or licensing counterparty is that the independent claim is not just “meloxicam + rizatriptan.” It is tied to a PK target for meloxicam and comparative headache outcomes versus rizatriptan alone. That increases the barrier to straightforward product design-arounds and drives risk into formulation and clinical PK/PD design.
What is claimed by US Patent 11,433,078 for migraine treatment using meloxicam and rizatriptan?
Short answer: The patent claims a method of treating acute migraine pain or migraine aura in a human by orally administering a single dosage form containing meloxicam plus ~8 to ~13 mg rizatriptan (free base equivalent) such that healthy-subject PK targets for meloxicam are met (mean Tmax ≤110 min and AUC0-24 ~30–50 μg·hr/mL). It further requires that, after administration, the patient experiences a greater reduction in migraine pain than with the same amount of rizatriptan alone at the same timepoints.
Independent claim 1: practical scope and litigation-ready elements
Claim 1 requires all of the following, as written:
-
Indication / timing
- Treating acute attack of migraine pain or migraine aura.
-
Route and format
- Orally administering a combination in a single dosage form.
-
Drug identity
- Meloxicam
- Rizatriptan amount is about 8 mg to about 13 mg, calculated based on free base form of rizatriptan.
-
PK requirement for meloxicam in healthy subjects
- Single dosage form structured so that oral administration to healthy human subjects yields:
- Mean Tmax of meloxicam ≤ 110 minutes
- AUC0-24 of meloxicam ~30 to 50 μg·hr/mL
-
Comparative clinical outcome requirement
- 1.5 hours after dosing, patient experiences greater reduction in migraine pain than with the same amount of rizatriptan administered alone.
This means enforcement theories can be framed around:
- whether the accused product contains the claimed active set and amounts; and
- whether it produces meloxicam exposure in healthy subjects within the claimed limits; and
- whether, at 1.5 hours, clinical response is superior to rizatriptan alone at matched rizatriptan dose.
Dependent claims: incremental narrowing and “hook” points
Claims 2–8 add patient instruction / patient selection and migraine frequency ranges.
Patient instruction and responder cohort
- Claim 2 / 3 / 4: timing-specific comparative superiority at 30 min, 2 h, 24 h (and inclusion of both 2 h and 24 h in claim 4).
- Claim 5–8: “history of inadequate response to prior migraine treatments,” plus “selected for” that history, plus 2–8 moderate to severe attacks/month.
Formulation architecture and excipient technology
- Claim 9: meloxicam is complexed with sulfobutylether-β-cyclodextrin (SBE-β-CD).
- Claim 10–12: bicarbonate is included, and then all three components (meloxicam complex + bicarbonate + rizatriptan) are combined in a monolayer tablet.
- Claim 13–15: further quantitative composition:
- rizatriptan: about 10 mg (free base) or molar equivalent salt
- meloxicam: about 20 mg (free acid) or molar equivalent salt
- bicarbonate: ~400–600 mg
- bicarbonate specified as sodium bicarbonate in claim 14
- plus again timepoint superiority at 30 min in claims 15.
Additional clinical/differential endpoints
- Claims 20, 22, 23, 28, 29, 30: add non-rescue for 24 hours, nausea superiority at 2 hours, absence of disturbed vision at 2 hours, pain freedom at 1.5 hours, and an assessment window at 1.5 hours.
Salt forms explicitly covered
- Claim 26: meloxicam in the free acid form.
- Claim 27: rizatriptan as rizatriptan benzoate.
Dissolution-rate framing
- Claim 21: bicarbonate present in an amount effective to increase dissolution rate of meloxicam.
How broad are the claims in US 11,433,078 across dosing, PK limits, and timepoint superiority?
Short answer: The claim scope is broad on “method of use” but narrow on PK metrics and comparative superiority. The PK limits tether the invention to a formulation that produces fast meloxicam exposure and a defined meloxicam AUC range in healthy subjects.
Key claim-scope axes
1) Rizatriptan dose range is moderately tight
- About 8–13 mg rizatriptan free base equivalent (independent).
- Dependent claims lock to about 10 mg.
Design-around approach would need to move out of range or avoid equivalence, but this is still paired to the meloxicam PK requirements and clinical superiority conditions.
2) Meloxicam dose is not numerically set in claim 1, but is later constrained
- Claim 1: “comprises meloxicam” without a numeric meloxicam mg range in the excerpted claim text.
- Claim 13 provides a specific composition example: about 20 mg meloxicam (free acid) in the tablet architecture.
In practice, claim 1 can still reach products with different meloxicam mg amounts if they still achieve the healthy-subject Tmax/AUC targets and clinical superiority.
3) PK in healthy subjects is a major exclusivity lever
Claim 1 requires a formulation that, in healthy subjects:
- achieves Tmax ≤ 110 min
- achieves AUC0-24 ~30–50 μg·hr/mL
This is atypical in combination method-of-use claims and becomes central in enforcement because it converts “formulation performance” into a claim element.
4) Superiority vs rizatriptan alone is a comparative limitation
The claim is not satisfied merely by “treats migraine.” It requires:
- at 1.5 hours (claim 1) and optionally 30 min, 2 h, 24 h (dependent claims),
- a greater reduction relative to the same amount of rizatriptan alone.
This invites arguments around comparator study selection, endpoint definitions, and statistical thresholds, but those issues sit in the litigation domain once the product meets all other claim elements.
What formulations are protected by US 11,433,078 (meloxicam SBE-β-CD complex, bicarbonate, monolayer tablet)?
Short answer: Dependent claims specifically protect a technology stack: meloxicam complexed with SBE-β-CD, co-formulated with bicarbonate (including sodium bicarbonate) in a monolayer tablet, with stated component amounts.
Dependent claim formulation “clusters”
Cluster A: SBE-β-CD complex
- Claim 9: meloxicam is complexed with sulfobutylether-β-cyclodextrin.
This suggests the patent is targeting accelerated meloxicam exposure, consistent with the meloxicam Tmax/AUC targets in claim 1.
Cluster B: bicarbonate to increase dissolution rate
- Claim 10 / 11 / 21 / 24 / 25: bicarbonate is present; bicarbonate is framed to increase meloxicam dissolution rate; sodium bicarbonate is expressly covered.
Cluster C: monolayer tablet architecture
- Claim 12 / 18: the complex + bicarbonate + rizatriptan are combined in a monolayer tablet (not layered).
Cluster D: quantitative tablet composition (high specificity)
- Claim 13–15:
- rizatriptan: ~10 mg
- meloxicam: ~20 mg
- bicarbonate: ~400–600 mg
This gives a clear target for formulation design and for generic “label-to-infringe” style comparisons.
How does US 11,433,078 differentiate from administering rizatriptan alone?
Short answer: The comparative superiority is timed and required. The patient outcomes must be better than a control arm of same rizatriptan dose administered alone.
Timepoint superiority requirements
- Claim 1: superior migraine pain reduction at 1.5 hours
- Claim 3: superior at 30 minutes
- Claim 4: superior at 2 hours and 24 hours
- Claim 15 / 19: reassert timepoint superiority (30 min; and 2 h + 24 h)
- Claim 23: nausea superiority at 2 hours relative to rizatriptan alone
- Claim 28: absence of disturbed vision at 2 hours vs baseline condition tied to claim 1 comparator construct
- Claim 29: pain freedom at 1.5 hours
- Claim 30: assessment at 1.5 hours
Litigation-relevant comparator framing
Because the claim language uses “would experience” with “the same amount of the rizatriptan orally administered alone,” litigation can pivot on:
- whether the accused dosing matches the “same amount” comparator concept;
- whether PK/PD differences create different effective exposure at those timepoints; and
- how “greater reduction” is measured (pain score instrument and endpoint definition), which becomes central when expert testimony is required.
What patient populations are covered by US 11,433,078 (prior inadequate response, migraine frequency, nausea)?
Short answer: Dependent claims allow targeted enforcement for subpopulations defined by prior inadequate response and attack frequency, with added symptom-based endpoints like nausea and disturbed vision.
Selection and frequency
- Claim 5/6: history of inadequate response to prior migraine treatments
- Claim 7/8: average 2–8 moderate to severe migraine attacks per month
Symptom extensions
- Claim 22/23: also suffering from nausea, with greater nausea reduction at 2 hours
- Claim 28: disturbed vision accompanies migraine; absence achieved at 2 hours
Rescue-medication constraint
- Claim 20: patient does not take rescue medication for at least 24 hours post-dose
This constraint can be important for clinical trial design and for how post-dose usage confounds endpoint measurement.
What are the US regulatory and exclusivity implications for a migraine combo covering meloxicam + rizatriptan?
Short answer: The excerpt provides claims only, not the underlying drug product, NDA/BLA, Orange Book listings, or FDA reference product. Without those, the Orange Book status, patent listing count, and regulatory exclusivity timelines cannot be mapped.
How many patents likely cover this technology stack, and what would that mean for generic or biosimilar risk?
Short answer: Not enough information is available in the prompt to enumerate the full US patent family for US 11,433,078, including continuations, divisionals, or related formulation/process patents.
However, the claim structure indicates a typical cluster of enforceable IP around:
- drug product composition (meloxicam + rizatriptan; SBE-β-CD complex; sodium bicarbonate; monolayer tablet),
- formulation performance (meloxicam Tmax/AUC targets),
- clinical outcomes at discrete early and late timepoints,
- potentially salt forms (meloxicam free acid; rizatriptan benzoate).
For generic risk, the presence of PK-performance limits and comparative clinical superiority increases the practical barrier to a straightforward ANDA-at-launch theory, because generic formulations must match performance and can still face method-of-use infringement exposure depending on label and study design.
What generic entry risks exist for a meloxicam + rizatriptan migraine single-dose tablet?
Short answer: The claims are structured so that infringement depends on (i) product composition and performance and (ii) patient outcomes relative to rizatriptan alone. A generic company faces risk if its product and its labeled method practice align with the claim elements, especially the meloxicam PK targets and the required timepoint superiority.
Design-around pressure points
- Avoid meloxicam PK window: move Tmax above 110 minutes and/or AUC0-24 outside 30–50 μg·hr/mL in healthy subjects.
- Avoid claimed formulation specifics: omit SBE-β-CD complex, omit sodium bicarbonate, or change tablet architecture away from monolayer (depending on what constitutes infringement under the full claim set).
- Avoid method practice: adjust labeling and intended use such that practitioners do not follow the claimed comparative superiority method construct at required timepoints (this is inherently more complex for method-of-use claims that require “would experience” comparisons).
Key Takeaways
- US Patent 11,433,078 is centered on an oral single-dose migraine method combining meloxicam with ~8–13 mg rizatriptan (free base equivalents).
- Claim 1 is unusually tethered to meloxicam PK targets in healthy subjects: mean Tmax ≤110 min and AUC0-24 ~30–50 μg·hr/mL.
- The method requires superior migraine pain reduction at 1.5 hours versus the same rizatriptan dose given alone; dependent claims add earlier (30 min) and later (2 h, 24 h) superiority requirements.
- Dependent claims narrow strongly into a specific formulation stack: meloxicam SBE-β-CD complex, bicarbonate (sodium bicarbonate), and a monolayer tablet, with a representative quantitative composition of ~10 mg rizatriptan + ~20 mg meloxicam + ~400–600 mg bicarbonate.
- Clinical scope extends beyond pain to nausea and disturbed vision endpoints, with a no-rescue for 24 hours constraint in one dependent claim.
FAQs
1) Does US 11,433,078 cover any oral meloxicam + rizatriptan combination for migraine?
No. It requires a single dosage form achieving defined meloxicam PK (Tmax and AUC) and a greater migraine pain reduction at 1.5 hours versus rizatriptan alone.
2) Can a product infringe without using SBE-β-CD?
Claim 1 does not expressly require SBE-β-CD. It requires the PK performance targets and the comparative superiority construct. SBE-β-CD is explicitly required in dependent claim 9.
3) Are sodium bicarbonate and monolayer tablet limitations mandatory for claim 1?
No. Sodium bicarbonate and monolayer tablet are in dependent claims (10–12, 14, 24–25, 18). Claim 1 covers the PK- and outcome-defined combination without those explicit limitations.
4) What timepoints are most important for infringement analysis?
1.5 hours is required by claim 1. Additional dependent hooks exist at 30 minutes, 2 hours, and 24 hours, plus symptom endpoints at 2 hours.
5) Does the patent require the patient to avoid rescue medication?
Only in dependent claim 20: no rescue medication for at least 24 hours after dosing.
References
- United States Patent 11,433,078.
